Refractory Coeliac Disease: Diagnosis, Treatment, and Emerging Therapies
Coeliac disease (CD) is a chronic immune-mediated disorder triggered by gluten ingestion in genetically predisposed individuals, leading to intestinal damage, malabsorption, and systemic complications. Although traditionally considered a gastrointestinal disorder, CD is now recognized as a multisys...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nicolaus Copernicus University in Toruń
2025-02-01
|
| Series: | Quality in Sport |
| Subjects: | |
| Online Access: | https://apcz.umk.pl/QS/article/view/58406 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850067134876483584 |
|---|---|
| author | Agnieszka Starzyk Piotr Charzewski |
| author_facet | Agnieszka Starzyk Piotr Charzewski |
| author_sort | Agnieszka Starzyk |
| collection | DOAJ |
| description |
Coeliac disease (CD) is a chronic immune-mediated disorder triggered by gluten ingestion in genetically predisposed individuals, leading to intestinal damage, malabsorption, and systemic complications. Although traditionally considered a gastrointestinal disorder, CD is now recognized as a multisystem condition with neurological, musculoskeletal, endocrine, and cardiovascular manifestations. Despite advancements in diagnostic tools, the disease remains underdiagnosed due to its diverse clinical presentations.
The global prevalence of CD is approximately 1%, with increasing incidence linked to improved screening and environmental factors. Diagnosis involves serological testing, histological examination, and, in select cases, genetic screening. While strict adherence to a gluten-free diet (GFD) is currently the only effective treatment, many patients face dietary compliance challenges, nutritional deficiencies, and persistent symptoms, necessitating further investigation for refractory CD.
Findings highlight that while GFD remains the cornerstone of treatment, adherence difficulties and ongoing symptoms in some patients require alternative interventions. Research into immune modulation, gut microbiota therapies, and intestinal permeability regulation is ongoing, with promising developments for non-dietary treatment options.
|
| format | Article |
| id | doaj-art-eafcd8a068934f8bac436d4781ee9038 |
| institution | DOAJ |
| issn | 2450-3118 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Nicolaus Copernicus University in Toruń |
| record_format | Article |
| series | Quality in Sport |
| spelling | doaj-art-eafcd8a068934f8bac436d4781ee90382025-08-20T02:48:29ZengNicolaus Copernicus University in ToruńQuality in Sport2450-31182025-02-013810.12775/QS.2025.38.58406Refractory Coeliac Disease: Diagnosis, Treatment, and Emerging TherapiesAgnieszka Starzyk0https://orcid.org/0009-0002-8696-4187Piotr Charzewski1https://orcid.org/0009-0007-5170-3899Medical University of WarsawKozminski University Coeliac disease (CD) is a chronic immune-mediated disorder triggered by gluten ingestion in genetically predisposed individuals, leading to intestinal damage, malabsorption, and systemic complications. Although traditionally considered a gastrointestinal disorder, CD is now recognized as a multisystem condition with neurological, musculoskeletal, endocrine, and cardiovascular manifestations. Despite advancements in diagnostic tools, the disease remains underdiagnosed due to its diverse clinical presentations. The global prevalence of CD is approximately 1%, with increasing incidence linked to improved screening and environmental factors. Diagnosis involves serological testing, histological examination, and, in select cases, genetic screening. While strict adherence to a gluten-free diet (GFD) is currently the only effective treatment, many patients face dietary compliance challenges, nutritional deficiencies, and persistent symptoms, necessitating further investigation for refractory CD. Findings highlight that while GFD remains the cornerstone of treatment, adherence difficulties and ongoing symptoms in some patients require alternative interventions. Research into immune modulation, gut microbiota therapies, and intestinal permeability regulation is ongoing, with promising developments for non-dietary treatment options. https://apcz.umk.pl/QS/article/view/58406coeliac diseasegluten intolerancegluten free dietnutrient malabsorptiongut microbiome |
| spellingShingle | Agnieszka Starzyk Piotr Charzewski Refractory Coeliac Disease: Diagnosis, Treatment, and Emerging Therapies Quality in Sport coeliac disease gluten intolerance gluten free diet nutrient malabsorption gut microbiome |
| title | Refractory Coeliac Disease: Diagnosis, Treatment, and Emerging Therapies |
| title_full | Refractory Coeliac Disease: Diagnosis, Treatment, and Emerging Therapies |
| title_fullStr | Refractory Coeliac Disease: Diagnosis, Treatment, and Emerging Therapies |
| title_full_unstemmed | Refractory Coeliac Disease: Diagnosis, Treatment, and Emerging Therapies |
| title_short | Refractory Coeliac Disease: Diagnosis, Treatment, and Emerging Therapies |
| title_sort | refractory coeliac disease diagnosis treatment and emerging therapies |
| topic | coeliac disease gluten intolerance gluten free diet nutrient malabsorption gut microbiome |
| url | https://apcz.umk.pl/QS/article/view/58406 |
| work_keys_str_mv | AT agnieszkastarzyk refractorycoeliacdiseasediagnosistreatmentandemergingtherapies AT piotrcharzewski refractorycoeliacdiseasediagnosistreatmentandemergingtherapies |